Every day, pathology departments worldwide generate petabytes of data—from digital slide images, molecular tests, and laboratory reports, to genome sequences. This data represents one of the richest, largest, and most valuable resources in the healthcare sector.
However, most of this data remains unutilized—buried in fragmented systems or confined in digital silos that do not communicate with each other. Even within a single institution, connectivity between clinical data in electronic health records and diagnostic or molecular analysis data from the pathology department is almost non-existent.
These systems speak different digital languages and rarely share the same context. As a result, critical insights are lost—such as how a molecular change impacted treatment, or how a diagnosis correlated with patient outcomes. Thus, the opportunity to learn from every case and to link diagnosis with prognostic predictions is missed.
To make matters more challenging, data access still relies on complex manual processes. Teams spend long hours preparing Excel spreadsheets or CSV files to match metadata with original images or reports, a process often entrusted to intermediaries called ‘trusted agents.’ This inefficient method has become one of the biggest obstacles to progress, rendering pathology’s wealth of data a limited-use resource exploited only in small research projects, instead of being a tool for radical change in patient care.
Meanwhile, artificial intelligence is advancing at an astonishing pace—whether pathology participates or not. Major institutions and technology companies are now building massive foundational models trained on multimodal data combining text, images, and molecular information. These systems have already begun to detect subtle patterns, predict mutations, and even generate diagnostic reports.
AI will not wait for pathology to catch up. If this specialty does not own its data, it will find itself merely a passive information provider instead of a leader in medical innovation. When others manage your data and reap its profits, you not only lose control—you lose influence, identity, and standing.
Data today is the new oil, but it is worthless without dedicated infrastructure, management, and governance. History is clear: nations that built infrastructure and invested in their resources became global powers, while those that did not remained dependent on others.
Pathology stands at a similar crossroads today.
Departments that invest in standardized, integrable data systems, in digital processes that generate structured insights, and in governance frameworks that uphold privacy, quality, and fairness—these will become the backbone of precision medicine. Those that fail to do so will end up merely as data suppliers feeding AI owned by others.
The goal is not merely to “adopt AI”—but to own the ecosystem that makes it possible.
The next decade will determine whether pathology leads this transformation, or is led by it.
The departments that will thrive are those that recognize data is not a technical problem, but a strategic asset for the institution. That digital pathology is not a cost center, but the foundation of future control. And that governance is not bureaucracy, but a lever of power.
The gold mine already exists. But unless the pipelines are built, the strategy is set, and its management is governed—others will exploit it.
The future of pathology will not be decided by the number of slides, but by who manages them best.
The time to act is now.
